News...Good or Bad? The Bad:
So Endo has relinguish the global rights! What does that mean?How does that look to potential partners?
Does that mean the P3B results so far is not that spectacular?
If the P3b result is very good, why would they give up?
Endo will still get a royalty from future revenue! For what? Screwing us up? How many times can we split the pie first to the loan sharks and now Endo?
OK, so now we have control of the trial. Where do we get the funds to do the trials?
If we get partners again. More revenue share goes out.
Can we even get a partner when they found out we have to give some of the royalty to Endo. Would any smart business take the risks for the development and share the rewards with a company that did not do anything?
The Good:
We have control.
We can opt for first line treatment use.
We can push it through in Canada first.
What are your thoughts.